LivaNova PLC (NASDAQ:LIVN) Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama lessened its stake in shares of LivaNova PLC (NASDAQ:LIVNFree Report) by 62.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 69,933 shares of the company’s stock after selling 116,612 shares during the quarter. Retirement Systems of Alabama owned about 0.13% of LivaNova worth $3,048,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of LIVN. Bank of Montreal Can boosted its stake in shares of LivaNova by 213.3% during the first quarter. Bank of Montreal Can now owns 35,725 shares of the company’s stock valued at $2,912,000 after acquiring an additional 24,324 shares during the last quarter. Panagora Asset Management Inc. purchased a new stake in shares of LivaNova during the first quarter worth about $256,000. Rhumbline Advisers raised its position in shares of LivaNova by 2.1% in the first quarter. Rhumbline Advisers now owns 147,621 shares of the company’s stock valued at $12,080,000 after buying an additional 2,980 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in shares of LivaNova by 10.5% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 19,506 shares of the company’s stock valued at $1,596,000 after buying an additional 1,859 shares during the period. Finally, Yousif Capital Management LLC boosted its position in LivaNova by 2.4% during the first quarter. Yousif Capital Management LLC now owns 28,279 shares of the company’s stock worth $2,314,000 after acquiring an additional 661 shares during the last quarter. Hedge funds and other institutional investors own 98.26% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on LIVN. Robert W. Baird raised their price objective on LivaNova from $56.00 to $62.00 in a report on Thursday. Needham & Company LLC reaffirmed a “buy” rating and set a $77.00 price objective on shares of LivaNova in a research note on Monday, April 17th. Barclays raised their target price on shares of LivaNova from $51.00 to $57.00 and gave the stock an “equal weight” rating in a research report on Thursday. Mizuho increased their price target on shares of LivaNova from $53.00 to $60.00 in a research note on Thursday. Finally, StockNews.com assumed coverage on shares of LivaNova in a research note on Thursday, May 18th. They set a “buy” rating for the company. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $67.17.

LivaNova Stock Down 2.6 %

Shares of LivaNova stock opened at $57.31 on Friday. LivaNova PLC has a twelve month low of $40.26 and a twelve month high of $66.73. The stock has a market cap of $3.08 billion, a price-to-earnings ratio of -37.21 and a beta of 0.90. The company has a current ratio of 2.86, a quick ratio of 2.41 and a debt-to-equity ratio of 0.42. The company has a fifty day moving average price of $49.58 and a 200 day moving average price of $49.16.

LivaNova (NASDAQ:LIVNGet Free Report) last issued its earnings results on Wednesday, July 26th. The company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.24. The company had revenue of $293.90 million during the quarter, compared to the consensus estimate of $265.05 million. LivaNova had a positive return on equity of 10.40% and a negative net margin of 7.83%. The company’s revenue was up 15.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.53 earnings per share. Equities research analysts forecast that LivaNova PLC will post 2.42 earnings per share for the current fiscal year.

LivaNova Profile

(Free Report)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

Featured Articles

Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVNFree Report).

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.